Johnson & Johnson’s COVID-19 vaccine candidate generated an immune response in nearly all clinical trial volunteers after a single dose, according to interim data analysis published Jan. 13.
Johnson & Johnson is falling behind on its original promise to deliver 100 million doses of its COVID-19 vaccine candidate by the end of June.
Pfizer notified national governments across the globe that it will deliver fewer doses than usual of its COVID-19 vaccine until mid-February as it renovates one of its factories in Puurs, Belgium.
Horsham, Pa.-based Institute for Safe Medication Practices released three main errors being reported regarding the COVID-19 vaccination process: dilution, mix-ups with similar products and wasted doses.
California’s state epidemiologist, Erica Pan, MD, told healthcare providers Jan. 17 to stop using a batch of Moderna’s COVID-19 vaccine after a “higher than usual” number of severe allergic reactions took place at a vaccination clinic in San Diego.
More articles on surgery centers:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don’t
Stryker’s ASC-focused business: 3 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
